CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money
25.45
0%
Market Trading Hours* (UTC) Opens on Monday at 08:00

Mon: 08:00 - 16:30

Tue: 08:00 - 12:55

Fri: 08:00 - 16:30

  • Summary
  • Historical Data
Trading сonditions
Spread 0.20
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.019346 %
Charges from full value of position ($-3.68)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.019346%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.002876 %
Charges from full value of position ($-0.55)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.002876%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency EUR
Margin 5.00%
Stock exchange Netherlands
Commission on trade 0%

Key Stats
Prev. Close 25.45
Open 25.3
1-Year Change -29.53%
Day's Range 24.8 - 25.45
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 20, 2024 25.45 0.10 0.39% 25.35 25.50 24.75
Dec 19, 2024 25.45 0.45 1.80% 25.00 25.50 24.85
Dec 18, 2024 25.60 0.15 0.59% 25.45 25.75 25.20
Dec 17, 2024 25.45 0.30 1.19% 25.15 25.60 24.95
Dec 16, 2024 25.60 0.85 3.43% 24.75 25.70 24.70
Dec 13, 2024 25.30 -0.15 -0.59% 25.45 25.70 25.15
Dec 12, 2024 25.80 0.35 1.38% 25.45 26.10 25.40
Dec 11, 2024 25.45 0.30 1.19% 25.15 25.65 25.10
Dec 10, 2024 25.20 -0.05 -0.20% 25.25 25.50 24.85
Dec 9, 2024 25.55 -0.40 -1.54% 25.95 26.55 25.50
Dec 6, 2024 25.50 0.35 1.39% 25.15 25.75 25.15
Dec 5, 2024 25.60 0.10 0.39% 25.50 25.85 25.50
Dec 4, 2024 25.75 -0.30 -1.15% 26.05 26.05 25.45
Dec 3, 2024 26.25 0.20 0.77% 26.05 26.55 26.05
Dec 2, 2024 26.35 0.60 2.33% 25.75 26.55 25.75
Nov 29, 2024 26.15 0.50 1.95% 25.65 26.35 25.65
Nov 28, 2024 26.05 -0.40 -1.51% 26.45 26.65 25.85
Nov 27, 2024 26.35 0.80 3.13% 25.55 26.35 25.55
Nov 26, 2024 25.75 0.25 0.98% 25.50 26.00 25.45
Nov 25, 2024 25.95 0.30 1.17% 25.65 26.30 25.10

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Galapagos NV Company profile

About Galapagos NV

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Galapagos NV revenues increased 2% to EUR538.6M. Net loss before extraordinary items decreased 60% to EUR125.4M. Revenues reflect Total net revenues increase of 1% to EUR484.8M, Other operating income increase of 3% to EUR53.7M. Basic Earnings per Share excluding Extraordinary Items increased from -EUR4.78 to -EUR1.92.

Equity composition

23754226 shares @12/31/04 1 for 4 split = shares 5938556 ipo may 2005 = shares 9170167 @ 06/30/05 H1 figures

Industry: Biotechnology & Medical Research (NEC)

Generaal De Wittelaan L11 A3
MALINES (MECHELEN)
ANTWERPEN 2800
BE

People also watch

US100

21,409.50 Price
+0.640% 1D Chg, %
Long position overnight fee -0.0234%
Short position overnight fee 0.0012%
Overnight fee time 22:00 (UTC)
Spread 1.8

Gold

2,625.43 Price
-0.070% 1D Chg, %
Long position overnight fee -0.0151%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.30

XRP/USD

2.14 Price
-3.760% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01066

ETH/USD

3,238.01 Price
-1.940% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading